Key information made simple
This study is looking at whether The first phase is a multi-centre, open-label, safety, tolerability and dose-finding study of cannabidiol (CBD) can help people with Parkinson’s disease psychosis, Mental and Behavioural Disorders, or Parkinson disease. Participants receive a study treatment and complete follow-up visits and assessments. Taking part may give some people access to The first phase is a multi-centre, open-label, safety, tolerability and dose-finding study of cannabidiol (CBD), but direct benefit is not guaranteed.
